Abstract: A layout pattern of a magnetoresistive random access memory (MRAM) includes a substrate having a first cell region, a second cell region, a third cell region, and a fourth cell region and a diffusion region on the substrate extending through the first cell region, the second cell region, the third cell region, and the fourth cell region. Preferably, the diffusion region includes a H-shape according to a top view.

Abstract: Disclosed herein are compounds that can bind to tubulin and activate GEF-H1. Methods of using these compounds for treating cancer are also disclosed.

Abstract: An electrochromic device with side-by-side structure including a common electrode unit, at least one color-changing unit and an electrolyte layer is provided. The common electrode unit includes an electrode layer and an electrode protection layer disposed on the electrode layer. The color-changing unit includes a transparent conductive layer and a color-changing layer disposed on the transparent conductive layer. The common electrode unit and each color-changing unit are arranged on the same plane with an insulating region between two adjacent units. The electrolyte layer covers and connects the electrode protection layer of the common electrode unit and the color-changing layer of each color-changing unit.

Abstract: Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof.

Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.

Abstract: Disclosed herein are methods of reducing or preventing thrombocytopenia, in a clinically relevant manner, that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

Abstract: Disclosed herein are composition and methods of treating a condition where enhanced immunogenicity is desired. Some embodiments disclosed herein relate to compositions comprising a T-cell activator and/or proliferator, one or more immune checkpoint inhibitor, and a FPPS inhibitor. Some embodiments relate to methods of treating cancer by co-administering plinabulin, one or more immune checkpoint inhibitor, and a FPPS inhibitor to a subject in need thereof.

Abstract: Disclosed herein are compounds that can bind to tubulin and activate GEF-H1. Methods of using these compounds for treating cancer are also disclosed.

Abstract: Synthesis of a sulfoxide-containing homobifunctional cysteine-reactive mass spectrometry-cleavable cross-linker for mapping intra-protein interactions in a protein and inter-protein interactions in a protein complex is provided. Methods for mapping intra-protein interactions in a protein and inter-protein interactions in a protein complex and cross-linking mass spectrometry for identifying one or more cross-linked peptides using the cross-linker are provided.

Abstract: Described herein includes a method of treating a cancer. The method includes selecting a patient responsive to treatment with a tubulin binding agent by determining an expression level of a biomarker panel; and administering the tubulin binding agent to the selected patient. The biomarker can be one or more probesets listed in Tables 1-2 or 4 or the gene expressions identifiable using the probesets listed in Tables 1-2 or 4.

Abstract: Disclosed herein are tucaresol derivative compound and composition containing the same. Also disclosed herein are methods of enhancing immune response in a subject by administering the tucaresol derivative compound or by co-administering the tucaresol derivative compound and one or more additional agents. Also disclosed herein are use of the tucaresol derivative compound and composition containing the same in the manufacture of a medicament for treating cancer or enhancing immune response in a subject.

Abstract: Disclosed herein are plinabulin and the use for reducing neutropenia. Some embodiments relate to reducing the docetaxel induced neutropenia using plinabulin.

Abstract: A multi-purpose planet planetary exploration rover is provided in this invention, which relates to the field of planet exploration. The multi-purpose planetary exploration rover includes a case body, mounted with a first wheel at left and right sides respectively; and a cantilever, having a front end connected to the case body, a rear end of the cantilever being mounted with a second wheel; wherein the cantilever is rotated or fixed relative to the case body, the second wheel is steered relative to the cantilever, and the first wheel and the second wheel are used to drive the multi-purpose planetary exploration rover. Compared with the prior art, the multi-purpose planetary exploration rover of this invention can effectively explore special geographic locations such as cliffs, volcanic craters, craters and lava caves on alien planets.

Abstract: The disclosure provides for mass spectrometry (MS)-cleavable heterobifunctional photoactivated cross-linkers. The MS-cleavable heterobifunctional photoactivated cross-linkers can be used in mass spectrometry to facilitate structural analysis of intra-protein interactions in proteins and inter-protein interactions in protein complexes.

Abstract: Disclosed herein are plinabulin and the use for reducing neutropenia. Some embodiments relate to reducing the docetaxel induced neutropenia using plinabulin.

Abstract: A method for identifying a potential biomarker for determining the probability of the success of embryo implantation by assaying a methylation profile of cervical secretions.

Abstract: Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.

Abstract: Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

Abstract: Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.

Abstract: Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.